Cargando…
Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
PURPOSE: To evaluate the role of ARDT after surgical resection of ACC. MATERIALS AND METHODS: Records of patients from our institutional ACC database were retrospectively assessed. A paired comparison analysis was used to evaluate the oncological outcomes between patients treated with surgery follow...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Urologia
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678514/ https://www.ncbi.nlm.nih.gov/pubmed/28727379 http://dx.doi.org/10.1590/S1677-5538.IBJU.2017.0095 |
_version_ | 1783277451518935040 |
---|---|
author | Srougi, Victor Bessa, Jose Tanno, Fabio Y. Ferreira, Amanda M. Hoff, Ana O. Bezerra, João E. Almeida, Cristiane M. Almeida, Madson Q. Mendonça, Berenice B. Nahas, William C. Chambô, Jose L. Srougi, Miguel Fragoso, Maria C. B. V. |
author_facet | Srougi, Victor Bessa, Jose Tanno, Fabio Y. Ferreira, Amanda M. Hoff, Ana O. Bezerra, João E. Almeida, Cristiane M. Almeida, Madson Q. Mendonça, Berenice B. Nahas, William C. Chambô, Jose L. Srougi, Miguel Fragoso, Maria C. B. V. |
author_sort | Srougi, Victor |
collection | PubMed |
description | PURPOSE: To evaluate the role of ARDT after surgical resection of ACC. MATERIALS AND METHODS: Records of patients from our institutional ACC database were retrospectively assessed. A paired comparison analysis was used to evaluate the oncological outcomes between patients treated with surgery followed by ARDT or surgery only (control). The endpoints were LRFS, RFS, and OS. A systematic review of the literature and meta-analysis was also performed to evaluate local recurrence of ACC when ARDT was used. RESULTS: Ten patients were included in each Group. The median follow-up times were 32 months and 35 months for the ARDT and control Groups, respectively. The results for LRFS (p=0.11), RFS (p=0.92), and OS (p=0.47) were similar among subsets. The mean time to present with local recurrence was significantly longer in the ARDT group compared with the control Group (419±206 days vs. 181±86 days, respectively; p=0.03). ARDT was well tolerated by the patients; there were no reports of late toxicity. The meta-analysis, which included four retrospective series, revealed that ARDT had a protective effect on LRFS (HR=0.4; CI=0.17-0.94). CONCLUSIONS: ARDT may reduce the chance and prolong the time to ACC local recurrence. However, there were no benefits for disease recurrence control or overall survival for patients who underwent this complementary therapy. |
format | Online Article Text |
id | pubmed-5678514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Sociedade Brasileira de Urologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-56785142017-11-16 Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? Srougi, Victor Bessa, Jose Tanno, Fabio Y. Ferreira, Amanda M. Hoff, Ana O. Bezerra, João E. Almeida, Cristiane M. Almeida, Madson Q. Mendonça, Berenice B. Nahas, William C. Chambô, Jose L. Srougi, Miguel Fragoso, Maria C. B. V. Int Braz J Urol Original Article PURPOSE: To evaluate the role of ARDT after surgical resection of ACC. MATERIALS AND METHODS: Records of patients from our institutional ACC database were retrospectively assessed. A paired comparison analysis was used to evaluate the oncological outcomes between patients treated with surgery followed by ARDT or surgery only (control). The endpoints were LRFS, RFS, and OS. A systematic review of the literature and meta-analysis was also performed to evaluate local recurrence of ACC when ARDT was used. RESULTS: Ten patients were included in each Group. The median follow-up times were 32 months and 35 months for the ARDT and control Groups, respectively. The results for LRFS (p=0.11), RFS (p=0.92), and OS (p=0.47) were similar among subsets. The mean time to present with local recurrence was significantly longer in the ARDT group compared with the control Group (419±206 days vs. 181±86 days, respectively; p=0.03). ARDT was well tolerated by the patients; there were no reports of late toxicity. The meta-analysis, which included four retrospective series, revealed that ARDT had a protective effect on LRFS (HR=0.4; CI=0.17-0.94). CONCLUSIONS: ARDT may reduce the chance and prolong the time to ACC local recurrence. However, there were no benefits for disease recurrence control or overall survival for patients who underwent this complementary therapy. Sociedade Brasileira de Urologia 2017 /pmc/articles/PMC5678514/ /pubmed/28727379 http://dx.doi.org/10.1590/S1677-5538.IBJU.2017.0095 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Srougi, Victor Bessa, Jose Tanno, Fabio Y. Ferreira, Amanda M. Hoff, Ana O. Bezerra, João E. Almeida, Cristiane M. Almeida, Madson Q. Mendonça, Berenice B. Nahas, William C. Chambô, Jose L. Srougi, Miguel Fragoso, Maria C. B. V. Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? |
title | Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? |
title_full | Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? |
title_fullStr | Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? |
title_full_unstemmed | Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? |
title_short | Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? |
title_sort | adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678514/ https://www.ncbi.nlm.nih.gov/pubmed/28727379 http://dx.doi.org/10.1590/S1677-5538.IBJU.2017.0095 |
work_keys_str_mv | AT srougivictor adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT bessajose adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT tannofabioy adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT ferreiraamandam adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT hoffanao adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT bezerrajoaoe adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT almeidacristianem adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT almeidamadsonq adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT mendoncabereniceb adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT nahaswilliamc adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT chambojosel adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT srougimiguel adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest AT fragosomariacbv adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest |